Ipsen Plunges as FDA Halts Bone Drug Trial in Children on Safety Concerns [Yahoo! Finance News]
IPSEN SA S/ADR (IPSEY)
NASDAQ:AMEX Investor Relations:
ipsen.com/investors
Company Research
Source: Yahoo! Finance News
) -- French drugmaker Ipsen SA had a record plunge after U.S. regulators suspended trials of its experimental treatment for rare bone diseases in patients under 14 on safety concerns. Two trials were put on hold in children after discussions with the Food and Drug ministration, Ipsen said Friday in a statement. The shares fell as much as 24% in Paris, lopping off 2 billion euros $2.2 billion) of market value in the steepest decline since they began trading in 2005. Ipsen acquired the drug, palovarotene, via its $1.3 billion purchase of Clementia Pharmaceuticals Inc. earlier this year. The French company has been under pressure to prepare for competition from cheap generic versions of its lead product, Somatuline, a treatment for hormone-fueled tumors of the stomach and pancreas. “It will be difficult to invest in the name short-term given this uncertainty for a drug which was due to replace numerically Somatuline,” Bryan Garnier’s Eric Le Berrigaud, who rates the stock neutral, said i
Show less
Read more
Impact Snapshot
Event Time:
IPSEY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IPSEY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IPSEY alerts
High impacting IPSEN SA S/ADR news events
Weekly update
A roundup of the hottest topics
IPSEY
News
- Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGSGlobeNewswire
- Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritusGlobeNewswire
- Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidanceGlobeNewswire
- Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver diseaseGlobeNewswire
- Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decadeGlobeNewswire